Compare STRT & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRT | ALDX |
|---|---|---|
| Founded | 1908 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.1M | 317.7M |
| IPO Year | 1996 | 2014 |
| Metric | STRT | ALDX |
|---|---|---|
| Price | $90.72 | $5.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 34.5K | ★ 672.1K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.53 | N/A |
| EPS | ★ 3.26 | N/A |
| Revenue | ★ $439,195,000.00 | N/A |
| Revenue This Year | $4.22 | N/A |
| Revenue Next Year | $2.04 | $36.25 |
| P/E Ratio | $27.89 | ★ N/A |
| Revenue Growth | ★ 5.24 | N/A |
| 52 Week Low | $31.71 | $1.18 |
| 52 Week High | $92.50 | $7.19 |
| Indicator | STRT | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 59.53 | 57.78 |
| Support Level | $62.09 | $4.72 |
| Resistance Level | $92.45 | $5.75 |
| Average True Range (ATR) | 4.48 | 0.29 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 85.91 | 76.22 |
Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.